Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025International Journal of Toxicology

Integrin αvβ3 Antagonist Ameliorates Atherosclerotic Progression by Reducing Platelet Hyperactivation

View Full Paper
Ask AI
Bookmark
Share

Authors

MXMengyun XuXZXurui ZhangQFQi Feng

Discussion

Loading...

Member takes

Overview

Investigating integrin αvβ3's role in platelet hyperactivation in atherosclerosis, showing therapeutic potential for heart diseases.

Key Points

  • The integrin αvβ3 antagonist significantly reduced platelet activation in atherosclerosis models.
  • Platelet counts and aggregation in patients with coronary heart disease decreased with αvβ3 antagonist treatment.
  • Atherosclerotic progression was examined using mouse models, demonstrating a reduction in disease severity.
  • Upregulation of αvβ3 integrin and multimerin 1 is linked to heightened platelet activation in atherosclerosis.

Cite This Study

Xu et al. (2025) studied this question.

synapsesocial.com/papers/68d413f8713b0b5dfea61c32https://doi.org/10.1177/10915818251375887
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1THE ROLE OF ΑIIBΒ3 RECEPTORS IN MYOCARDIAL INFARCTION: MECHANISMS AND THERAPEUTIC STRATEGIES2025
  2. 2Selective Inhibition of Integrin β3 Topology Provides a Safer Antithrombotic Strategy2026
  3. 3Platelet priming in MPN triggers pro-thrombotic intermediate affinity state in αIIbβ3 integrin2025 · 1 citations
  4. 4Integrin β3 dysregulation impairs megakaryopoiesis and microparticle production via disrupting ROCK-dependent cytoskeletal dynamics.2025
  5. 5ApoC3 Attenuates Platelet Activation Through GPIIb/IIIa Receptor Interaction2025 · 1 citations